Heron Therapeutics Q4 2023 Earnings Call Transcript

Quartr
Provided by Quartr
March 12, 2024

There are 9 speakers on the call.

Operator

Thank you for standing by, and welcome to the Heron Therapeutics 4th Quarter 2023 Conference Call. I would now like to welcome Melissa Durell, Executive Director, Legal to begin the call. Melissa, over to you.

Speaker 1

Thank you, operator, and good afternoon, everyone. Thank you for joining us on the Heron Therapeutics conference call this afternoon to discuss the company's financial results for the Q4 ended December 31, 2023. With me today from Heron are Craig Collard, Chief Executive Officer Ira Duarte, Executive Vice President, Chief Financial Officer Bill Forbes, Executive Vice President, Chief Development Officer and Kevin Werner, Senior Vice President, Medical Affairs Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion

Speaker 2

of today's call. Before we begin,

Speaker 1

let me quickly remind you that during the course of this conference call, the company will make forward looking statements. We caution you

Speaker 2

that any statement that is not

Speaker 1

a statement of historical facts is a forward looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and future performance, all of which constitute forward looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements. The risks and uncertainties associated with the forward looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward looking statements to reflect future events or actual outcomes and does not intend to do so.

Speaker 1

And with that, I would now like to turn over the call to Craig Holler, Chief Executive Officer of Heron.

Speaker 3

Good afternoon, and welcome to the Heron Therapeutics 4th quarter 2023 earnings call. Today, we are pleased to update you on our latest achievements in 2023 financial performance, rationale on our development projects, cross linked training and some insight into where we are headed strategically with our products. Since joining Heron Therapeutics as CEO back in April of 2023, we have taken significant steps to get this business back on track. It started with headcount and expense reduction combined with getting the right management team in place. We've implemented a comprehensive streamlining of our financial processes, enhancing efficiency and accountability across the organization.

Speaker 3

As you

Speaker 4

can see from this slide,

Speaker 3

we have had a number of significant achievements in 2023 that have us well positioned as we move into 2024 and beyond. We've been able to reduce operational expenses from $182,000,000 in 2022 to $135,000,000 in 2023, and we should be in the range of $108,000,000 to $116,000,000 in operating expenses in 2024. As part of this process, we have also looked to improve our gross margin. Historically, the company has had gross margins in the 50% range. However, through better inventory management and with some renegotiations with our manufacturers, we've been able to reduce COGS and improve gross margins to over 70%.

Speaker 3

We anticipate future gross margins to continue to improve up to the mid-70s range. We completed a capital raise early in 2023, which will allow us to have enough cash to get to profitability by late 2024. We closed the year in 2023 with over $80,000,000 in cash and cash equivalents, which again is enough cash for us to reach profitability in Q4 of 2024. Moving down the list, we were able to restart the vial access needle or VAN project along with the prefilled syringe. Both of these projects are progressing nicely with the expected band approval by the end of this year and the pre filled syringe approval expected in 2026.

Speaker 3

Both of these projects will provide significant improvement to our product center lift, which is indicated for postoperative surgical pain. Our oncology franchise continues to outperform and I'm happy to report total net revenues of $107,900,000 which exceeded full year 2023 guidance. We are also very pleased with ZenoLED performance in Q4 of 2023. For the first time in our history, we were able to do over $5,000,000 in net revenue for the quarter, even while significant change was happening in the business. And last, in January 2024, we were able to sign a cross link agreement, combined with getting our label expansion for Zenerlef.

Speaker 3

These two events should have a significant impact to Zimmerlipt revenues as we move through 2024 and beyond. Now moving to product performance. The oncology franchise continues to outperform our expectations with Cymbalti net revenues coming in at $94,900,000 for the year and Sustol coming in at $13,000,000 We have been very pleased in the oncology franchise and we believe these products will continue to show the same consistency as in past years. The acute franchise is where we anticipate majority of our product growth to come from as we move forward. We were very pleased that Imphalete hit a record of $5,600,000 in net revenue for the quarter, which is the first time this product has ever been over $5,000,000 for a quarter.

Speaker 3

Total acute care net revenues for the year were $19,100,000 which included eponvie net revenues of $1,400,000 We believe Zeneli and PONDI are both well positioned as we move into 2024. With the CrossLink partnership, expanded label combined with increasing morale, improved sales missions and targeting, we believe this is going to be a great year for both products. Moving to the CrossLink partnership, this agreement was signed on January 7 and really got kicked off in early February. We began the training process with in person training of the cross linked executive team, which went extremely well. We will continue this process through March early April that will lead to having over 150 sales folks trained and ready to go.

Speaker 3

Post this initial group being trained, we will continue to roll out other areas of the country. As you look at this slide, it will give you a better understanding of what our footprint, Pulse full implementation of CrossLink will look like and consider that this will add an additional 6 50 reps across the country that will be fully trained. We anticipate having the entire group fully trained and up and running by the end of 2024. We also believe that we will see an impact in 2024 from this matter of representatives coming into place. But I do want to temper the enthusiasm as obviously this will take time before we really start to hit on all cylinders.

Speaker 3

I really believe the inflection for Zimmerlipt will take place as we move into 2025 after the launch of VAN and having all the new reps fully trained, but we certainly have positive momentum and we believe the cross linked reps will have an impact in 2024. We have been looking at doing more at the ASD level as we have tried to focus more of our efforts around the orthopedic space. After signing the partnership with CrossLink, it has become increasingly apparent that CrossLink has a significant footprint in this space and that our product mix works in parallel with the strategy of the ASC, which is to get these patients out of surgery and into rehab as quick as possible. Our perioperative one two punch for the PONGMY and ZEMALA will be extremely beneficial to our potential partners at the ASC level. I'm now going

Speaker 4

to pass the call to

Speaker 3

our newest hire, Kevin Werner, who is our new Senior VP of Med Affairs Strategy and Engagement. Kevin feels a vital need for us of having hands on experience with our products at the clinician level and is going to have a significant influence in our ASP strategy as we move forward.

Speaker 5

Go ahead, Kevin. Thank you, Craig.

Speaker 4

I'm so excited to be joining the Hannon Therapeutics team in supporting the commercial portfolio of acute care and oncology care products. I have over 15 years of clinical pharmacy experience with a focus on perioperative care as a pharmacist, in addition to over a decade of experience in drug development, discovery and clinical trials as Director of Pharmaceutical Sciences at Osteo Therapeutics. As Senior Vice President of Medical Affairs, Strategy and Engagement for Heron, it will be my job to support the accurate dissemination of medical information to our team and providers, assuring patients have access to the best possible care. Forming strategic alliances and collaborating with the MedDOT community to assure Heron's products become part of the standard of care as medical literature dictates. I look forward to working with our team at Heron on expanding indications, access, adoption and medical literature with our current commercial portfolio and future products.

Speaker 4

I will focus on our acute care portfolio today as I've had the pleasure of having extensive real world experience with FINRAELY and EPONVI witnessing the positive impact on our patients and health systems. Enhanced Recovery after surgery protocols are evidence based protocols that are essential to patient outcomes and sustaining the financial viability of our health systems. The primary clinical focuses of ENHANCE recovery after surgery are reducing postoperative pain while minimizing opioid consumption and to control postoperative nausea vomiting. Post operative pain and post operative nausea bounding are 2 of the most common concerns for both patients and clinicians. Zenerleaf and EPONVI offer what we consider best in class, long acting solutions to these problems.

Speaker 4

Implementation of Zenerleaf and EPONVI as the foundation of our enhanced recovery after surgery protocols, we believe may improve overall patient satisfaction, clinical outcomes and overall quality of life. On an institutional level, while supporting enhanced recovery after surgery, both Nidaleve and Aponvie can have a positive financial impact on our institutions. Both products are currently separately payable in the hospital outpatient and ambulatory surgical centers by CMS. In addition, many commercial payers are providing coverage for XENERLYN outside of surgical bundle. Improving the efficacy of our enhanced recovery after surgical protocols combined with separate reimbursement outside of surgical bundle is critical to the financial viability of our health system and clinical outcomes of our patients.

Speaker 4

I want to touch on EPONVI, a prefaceant injectable emulsion and the current unmet need and lack of awareness. Postoperative nausea and vomiting is often overlooked or under recognized secondary to the timing and different phases of care in which patients can experience this. Postoperative nausea and vomiting is ranked the number one most undesirable post op complication by patients, but also presents clinical risk factors as well that can lead to increased length of stay, readmissions and surgical complications. Postoperative volume rates can reach as high as 80% in high risk patients. The current guidelines recommend the use of 3 or 4 agents patients with risk factors making them moderate to high risk.

Speaker 4

In the United States, we perform over 65,000,000 diagnostic and surgical procedures, of which 50% of those patients are at moderate to high risk for postoperative nausea embomy. Apreptin is set on the market in an oral formulation and as a prodrug infusion fosidgravetin. The oral formulation is delayed onset of action of about 1 to 5 hours. Fostered substance requires compounding and a 20 to 30 minute infusion followed by systemic conversion of the prodrug to the active form. Because of this, they have not been widely adopted in the perioperative space despite apravitin being ranked the number one most effective in antiemetic for a large scale papillimetic analysis of nearly 100,000 patients.

Speaker 4

Along with the efficacy, irrepitant also has an excellent safety profile without sharing typical side effects of our commonly used antiemetic therapies such as QT prolongation, sedation, anticholinergic effect or extrapyramidal side effects. The safety profile is critical when we are combining multiple agents for our moderate and high risk patients. PONDI's 32nd IV push and rapid target receptor occupancy will offer greater implementation of incontinence and the acute perioperative pain by those providers, mainly anesthesia most likely to prescribe. PONDY's safety and efficacy profile is a long acting solution with a 48 hour duration to one of our most significant postoperative complications, postoperative malassemia vomiting. We're looking forward to the updated guidelines on the prevention of postoperative malassemia vomiting expected in 2024, which will enhance the education and awareness around the impact of Hanmi can have.

Speaker 4

For Zenerleaf, our focus will be on broadening provider awareness and associated patient impacts. The clinical trials of Zenerife speak for themselves, being the 1st and only FDA approved extended release anesthetic, proven to reduce pain and opioid consumption. Today, I want to highlight some of the significant drivers to growth that have been implemented or will be this year. First of all, the significant label expansion for Zynraly approved by the FDA on January 23, 2024, with the Zenergiz is now indicated in adults for installation to produce post surgical analgesia for up to 72 hours after soft tissue and or orthopedic procedures, including foot and ankle and other procedures, which direct exposure to articular cartilage is avoided. This is essentially double the number of significant indicated procedures.

Speaker 4

As a clinician, when I think of indicated procedures and appropriate use of Zimmerli, I consider any procedure in which a provider would typically prescribe an opioid postoperative. They should be considering use of Zenerleaf as the foundation for postoperative analgesia to minimize or eliminate the need for opioids, minimizing the acute pain, risk of developing chronic pain and support clinical recovery. The label expansion will also have a great impact on formulary substitution. Some formulary has been hesitant to adoption due to limited number of indications, necessitating need for having multiple agents on formulary and subsequent budget impacts. With the new broad label facility, other agents that have claimed long acting, but have not proven superior to standard of care anesthetics can be removed from formulary and ZYNALYTE can be adopted as the long acting foundational element along with cheaper generic anesthetics for the acute phase.

Speaker 4

Additionally, 3rd party data continues to surface with results that align with our clinical trials showing significant impact on postoperative pain, opioid consumption, length of stay and functional outcomes. The opioid epidemic continues to be at the top of our news feeds, costing the U. S. Health system an estimated $1,500,000,000,000 in 2020 and many patient lives. Our major accrediting bodies and government agencies are taking notice and stepping in.

Speaker 4

The Joint Commission now includes metrics for opioid stewardship to be accredited. The No Pain Act, which will begin in 2025, will provide payment for non opioids in the outpatient surgical study that has proven to reduce or eliminate the need for opioids. Along with the opioid settlements currently being distributed to states in the amount of $53,000,000 that will be utilized to support awareness, prevention, treatment of the opioid epidemic. All these factors will have major impacts on awareness and adoption of Zimmerli. One of the most important factors, I believe, will be the CrossLink partnership that Craig outlined previously.

Speaker 4

Having the additional boots on the ground, if you will, will be critical to the successful implementation of Zimmerli as the foundation of multimodal analgesia across the nation to change how we view postoperative pain and the knee for opioid across the surgical paradigm. I would like to now turn the call over to Doctor. Bill Kors.

Speaker 5

Thank you, Kevin. We are certainly excited to have you join our team. The development opportunities for ZenoLEp has envisioned 3 steps. The first was label expansion, which has been realized. Next step involves device modification in the form of the vial access needle or VAN.

Speaker 5

And the final step concludes with the preso syringe for PFS. In regards to the VAN, it is designed to improve efficiency in preparation and we'll achieve this in 2 ways. Firstly, the VAN will substitute the current market presentation of the device, which includes a vented vial spike or VBS with the VAN itself. The VAN will provide a more rapid and easy withdrawal of the drug product into the syringe that is used for installation into the patient by the physician. The VAN has been specifically designed for this purpose and in testing the VAN has outperformed other vented vial spikes available on the market today.

Speaker 5

Secondly, the VAN will allow for an even more secure presentation of the product into the sterile field present in the surgical room by encasing the ZENALF vial into the sterile shroud of the VAN. This will result in a more efficient process for operating room staff to prepare the product for physician use. We anticipate the VAN approval in Q4 of this year. Of course, the ultimate solution to ease of use of ZenoLEF is the PFS and we expect the PFS to get approved in Q4 of 2026. In this product presentation, the entire tray is sterilized and ready for immediate use.

Speaker 5

The challenges for this program involve a new container closure system and the sterilization process itself. Once this is available, all barriers to preparation will be removed. With that, I will now turn this over to Ira Duarte. Ira?

Speaker 2

Thanks, Bill. Craig has covered our product performance in his comments and I will just add a few additional points about our Q4 2023 and year to date results. Our product gross profit for the 4th quarter was $24,300,000 $61,900,000 for the 12 months ended December 31, 2023, representing 71% 49% of net revenue respectively. The annual margins were negatively impacted by write offs of Van Willis inventory during the year. We do not anticipate any large Van Willis write

Speaker 5

offs in the future.

Speaker 2

SG and A expenses for the 3 12 months ended December 31, 2023 with $23,600,000 116 point $7,000,000 respectively, compared to $26,700,000 $119,900,000 in the same period of 2022. Research and development expenses were $10,900,000 $55,900,000 for the 3 12 months ended December 31, 2023, compared to $11,100,000 and $107,500,000 in the comparable period of 2022. The decrease in spend was primarily related to decreases in costs related to the NOLF and production scaled up, validation activities and raw material costs were completed in 2022. In addition, overall personnel and related costs decreased due to the reductions in force implemented in June 2022 June 2023. We believe we can continue to reduce costs moving forward in this area as we continue to increase efficiencies.

Speaker 2

The net loss was $10,700,000 for Q4 2023 $19,900,000 for the comparable period in 2022.

Speaker 5

Looking to a total year

Speaker 2

to date net loss, 2023 is a net loss of $110,600,000 compared with $182,000,000 in the comparable period of 2022. I now would like to give a little bit more clarity on our overall operational spend and cash burn for 2023. We began implementing our corporate restructuring plan in early June, which includes several cost saving strategies, including a reduction in force as well as overall company wide spend reduction. We now have much more visibility into our operational spend and see clear path to profitability. If you look at the slide from left to right, you will see our overall operational spend for 2023 of about $172,000,000 which we reduced to $155,000,000 after excluding the reorganization charges of $18,000,000 Reducing these expenses for non cash stock compensation, not related to severance and depreciation and amortization of $27,000,000 our cash OpEx spend was $128,000,000 for the year.

Speaker 2

This compares to $177,000,000 of cash OpEx spend for 2022. Please keep in mind that we started implementing our company wide reduction mid year 2023. And as mentioned in our previous earnings call, we believe our operational run rate excluding stock compensation and depreciation and amortization going forward will be between $108,000,000 to $160,000,000 and cash burn will decrease every quarter as we have stabilized our spend and revenues are increasing every quarter. Moving now on to our guidance for 2024. We are reaffirming our previously given guidance for revenue of $138,000,000 to $158,000,000 for 2024 and improved gross margins between 68% to 70%.

Speaker 2

Our operating spend excluding stock compensation and depreciation and amortization is anticipated to be between $108,000,000 to $160,000,000 and EBITDA excluding stock comp will be between a loss of $22,000,000 to income of 3,000,000 dollars I would like to reiterate that we anticipate getting to positive EBITDA in Q4 2024 and based on this, our strong balance sheet and our current operation plan, we do not anticipate to have to raise any additional capital. And now we would like to open the call for any questions.

Operator

The floor is now open for your questions. Our first question comes from the line of Serge Belanger with Needham and Company. Please go ahead. Your line is open, sir. Pardon me.

Operator

Your line is open. Please go ahead, sir.

Speaker 6

Can you hear me?

Speaker 3

Yes, we can now. I'm sorry, Serge. We didn't hear the part of that.

Speaker 6

Got it. Got it. So two questions related to Zenerife. The first one, it's been 6 or 7 weeks since the label expansion. Just curious if you've seen any impact from in demand or usage since that?

Speaker 6

And then maybe secondly, if you can just talk about what the No Pain Act means for ZINRILES? I guess specifically what kind of coverage do you have now and how do you think that changes once we flip the calendar to January 25 when the No Pain Act takes effect? Thanks.

Speaker 3

Okay. Sure. Yes, I would say again anecdotally when we got the label expansion, obviously, there's a lot of excitement. When we go into certainly centers where we already have some business, it's easier to go deeper into those accounts and we're seeing some of that. Actually the day 1 of the label expansion I saw, I guess our first on label spine surgery.

Speaker 3

I was actually in the surgery in Asheville, North Carolina. So we're certainly getting some of that. I think that though combined with certainly CrossLink, we had the meeting at AAOS out in San Francisco. We were with CrossLink some and had some physicians coming by the booth and everything and just the excitement around that. But I don't think you're going to see necessarily a dramatic impact as of yet, but we're certainly seeing some impact.

Speaker 3

But I think again over time as I said in my comments, I think with CrossLink, with the label expansion, the launch of VAN later in the year, I think this really begins to take off later into the year into 2025 when we really start to see inflection. But we're certainly seeing some positive momentum. Regarding the No Pain Act, I'm going to turn it to Kevin Werner, who can give a

Speaker 4

little bit more insight into that. Serge, thanks for that question. So the No Pain Act is going to be significant from multiple facets. So what the No Pain Act does is provide reimbursement in the hospital outpatient procedure department and the ambulatory surgical centers for products that have been proven to reduce the need for opioids. So in the release instance, we're already covered in both the HOPD and ASC through 2025 for Q1.

Speaker 4

So the No Pain Act is going to go through 2027. So it will essentially establish that reimbursement for our facilities through 2027 and CMS has discussed a longer timeframe from that beyond possibly extending all the way to 2,030. So we look forward to working with our legislatures on that and continuing to get reimbursement for our patients to assure that it is covered, but that will help assure the adoption and the pull through for many institutions.

Speaker 5

Thank you. You're welcome.

Operator

Our next question comes from the line of Carl Byrnes with Northland Capital Markets. Please go ahead.

Speaker 7

Thanks for the question and congratulations on the results and the progress. Understanding that 2025 is really set up to be the ramp year for ZEMBLA and POMBI, How do you see and I know you touched on this a bit already. How do you see the cross link collaboration and label expansion transitioning into ZEMRA led cells in 2024? I think the prior language was acute care products at 50% year over year growth. So comfortable with that number or do you think that that's likely to prove conservative?

Speaker 7

Thanks.

Speaker 3

Yes. Again, one of the reasons we did get that range was we weren't sure exactly when and how this may take off. But to your point with expanded label and the thing I can say about the CrossLink partnership, I mean, every now and then you do one of these where things seem to work perfectly from a standpoint of the personnel and just how things come together. And we really do feel that way that the crossing folks have been fantastic. They certainly are bringing different relationships that we may have currently with some of the surgeons and so forth.

Speaker 3

So that's been everything we had hoped for at this point. I think one of the surprises that we had when we did the initial training and I was there along with our team, we did that in person and again, it was just very receptive. We had the executive team at CrossLink. And so from there, we did another training last week in person with some of the sales folks there. And so we're going to continue to do those.

Speaker 3

And so we should as I mentioned, we should have in the next 30 days or so about 150 reps that will be sort of fully out there and running. And so again, we will certainly see some impact. I'm just trying to temper this a bit because until we really get fully up and running and do this for a little while and transfer these other areas of the country, I don't think it's going to really take off and inflect until next year. But look, we're having positive things happen so far and we're pleased. So, so far this is going as planned.

Speaker 7

Great. Thanks. And then just a follow-up. There also seems to be and you again touched on this, a significant opportunity in the ASC segment, particularly to cross sell Bulzumri Lev and Aponbi with your sales force and with the cross link collaboration. Could you want to can you elaborate a little bit about what your thoughts are in terms of how big that opportunity might be?

Speaker 7

Thanks.

Speaker 3

Yes. Well, certainly, the market is moving that way. And again, we've tried to I hate to say overly simplify things, but really tried to go where we think we'd be most successful now and sort of niche this product a bit. And so that has led us to the orthopedic space and we'll certainly expand from there. But that really is in parallel where that space is going with ASC.

Speaker 3

So as we look at our business, we think there's a real opportunity as that space expands for us to really have a true partner there. Because again, if you think about the goal of an ASC is to get these patients out quickly, to get them into rehab. The last thing you want is any patients that would have any kind of nausea associated with the surgery going back into the hospital. And so this is where a PONV can come in and play and so for those higher risk patients. So with our kind of perioperative 1, 2 punch, we really do feel that these two products are really positioned perfectly with exactly what the ASC is trying to do.

Speaker 3

And so again, with CrossLink already having some presence there, we think that's going to be extremely helpful in opening some doors for us there and really trying to move down that path.

Speaker 7

Great. Thanks and congratulations again.

Speaker 4

Thanks, Carl.

Operator

Our next question comes from the line of Kelly Hsieh with Jefferies. Please go ahead.

Speaker 8

Hi, this is Claire on for Kelly. Congrats on the great progress. And just one quick question execute your cost reduction plan in 2024? Like should we expect R and D and SG and A to continue to go down in 2024 and 2025? And like at what point do you think your operating costs will be at a more stable level?

Speaker 8

Thank you.

Speaker 3

Thanks, Claire. I appreciate the question. Now look, the range we've given from $108,000,000 to $116,000,000 I mean, again, we'd love to be at the lower end of that. We're just again, as we've made some of these changes, we're trying to now kind of sort through what that may look like this year. And we've given ourselves a little bit of wiggle room, but I don't think you're going to see significant cost reductions from here.

Speaker 3

I think we're sort of at a level now where you can kind of expect going forward. But again, we feel pretty comfortable within this range.

Speaker 8

Got it. Thank you.

Speaker 7

Okay. Thank you.

Operator

There are no further questions at this time. I would now like to turn the call over to Craig Collard for closing remarks.

Speaker 3

I just want to thank everyone for joining the call today and we really look forward to speaking to everyone next quarter. Thank you.

Powered by Quartr

Key Takeaways

  • Through comprehensive cost reduction and streamlined financial processes, Heron reduced operating expenses from $182 million in 2022 to $135 million in 2023, targeting $108 million–$116 million in 2024.
  • Gross margins improved to over 70% in 2023 (up from ~50%), driven by better inventory management and manufacturer renegotiations, with mid-70s margins expected going forward.
  • The oncology franchise delivered $107.9 million net revenues in 2023—exceeding guidance—with Cymbalta at $94.9 million and Sustol at $13 million.
  • Acute care is poised for growth after Impla ven’s record $5.6 million Q4, supported by the CrossLink partnership (650 reps by year-end), ZenoLEF label expansion, and upcoming VAN (Q4 2024) and prefilled syringe (Q4 2026) launches.
  • For 2024, Heron reaffirms guidance of $138 million–$158 million revenue and 68%–70% gross margins, expects positive EBITDA in Q4, and does not anticipate additional capital raises thanks to an $80 million cash balance.
AI Generated. May Contain Errors.
Earnings Conference Call
Heron Therapeutics Q4 2023
00:00 / 00:00